The Latest Medical News

A Summary of The Latest Medical News: Novo Nordisk's semaglutide, a GLP-1 drug known for treating type 2 diabetes and obesity, failed to slow Alzheimer's disease progression in two large Phase 3 trials called EVOKE and EVOKE+.[1][2][3] **Trial Details and Participants** These 18- to 24-month studies enrolled 3,808 people aged 55-85 with mild cognitive impairment or mild dementia due to early-stage Alzheimer's, confirmed by amyloid pathology.[1][3][6] EVOKE tested oral semaglutide alone or with standard care, while EVOKE+ included patients with vascular issues.[2][3] **Primary Endpoint Miss** Neither trial met its main goal: semaglutide showed no statistically significant reduction in disease progression compared to placebo.[1][2][3] Scores on cognitive and functional scales, like the ADAS-Cog and ADCS-ADL-MCI, were nearly identical—differences of just -0.06 and 0.15 points, with p-values confirming no benefit (p=0.77 and p=0.46).[3] **Biomarker Hints, But No Clinical Win** Positive effects appeared on some Alzheimer's biomarkers in cerebrospinal fluid, with about 10% reductions in key markers for roughly 199 substudy participants.[1][3][5] Exploratory blood markers showed mixed changes, like slight increases in neurofilament light and GFAP, but these didn't translate to slower symptom progression.[3] **Novo's Response: Trials Halted** Novo Nordisk called results "disappointing but unsurprising," citing low success odds from the start.[1][2] The company discontinued one-year extensions, signaling no further pursuit in symptomatic Alzheimer's.[2][3] **Expert Takes: Prevention Over Treatment?** Analysts note prior real-world data linked GLP-1s to 11-64% lower dementia risk in diabetes patients, hinting at prevention in preclinical stages rather than treating established disease.[2][4] Neuropsychiatrist Ivan Koychev emphasized targeting high-risk people early with biomarkers.[2] **Bigger Picture for Alzheimer's Research** While a setback for GLP-1s like Rybelsus or Wegovy in dementia, the trials' robust design offers valuable data on neuroprotection.[3][5] Eyes now turn to tau-targeting drugs and combination therapies as the field evolves.[2][5] Help with your insurance? https://tally.so/r/n012P9